Impact of Coronavirus Disease 2019 on Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sang, Yun Beom | - |
dc.contributor.author | Lee, Chaeryoung | - |
dc.contributor.author | Kim, Seul-Gi | - |
dc.contributor.author | Lee, Boyoung | - |
dc.contributor.author | Kang, Beodeul | - |
dc.contributor.author | Kim, Chan | - |
dc.contributor.author | Chon, Hong Jae | - |
dc.date.accessioned | 2024-06-11T08:30:46Z | - |
dc.date.available | 2024-06-11T08:30:46Z | - |
dc.date.issued | 2024-03 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26260 | - |
dc.description.abstract | (1) Background: The coronavirus disease 2019 (COVID-19) pandemic has proven challenging to the management of patients with cancer, particularly those receiving systemic therapy. This study aimed to evaluate the impact of COVID-19 on patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab/bevacizumab. (2) Methods: Patients with unresectable HCC who started atezolizumab/bevacizumab treatment between June 2020 and December 2021 at a tertiary cancer center in Korea were included (n = 241) and classified according to their COVID-19 status and severity. (3) Results: Thirty-five (14.5%) patients with unresectable HCC were diagnosed with COVID-19 during atezolizumab/bevacizumab treatment; 26 (74.2%) and nine (25.7%) in the low- and high-severity groups, respectively. The high-severity group showed higher neutrophil-to-lymphocyte ratios and lactate dehydrogenase levels. Liver and kidney injuries were observed in 31.4% and 17.1% of total patients, respectively. Liver injury was more prominent in patients with pre-existing liver dysfunction at baseline, who were more prevalent in the high-severity group. Atezolizumab/bevacizumab treatment was delayed by a median of 0 (range, 0-21) day in the low-severity group and 12 (range, 0-35) days in the high-severity group. The high-severity group showed worse post-infection progression-free survival (1.1 vs. 4.8 months, p = 0.017) and overall survival (2.2 months vs. not reached, p = 0.004). (4) Conclusions: Patients with impaired liver function at baseline are more susceptible to high-severity COVID-19, which affects atezolizumab/bevacizumab treatment outcomes. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI | - |
dc.title | Impact of Coronavirus Disease 2019 on Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/jcm13051335 | - |
dc.identifier.scopusid | 2-s2.0-85187476343 | - |
dc.identifier.wosid | 001182780100001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL MEDICINE, v.13, no.5 | - |
dc.citation.title | JOURNAL OF CLINICAL MEDICINE | - |
dc.citation.volume | 13 | - |
dc.citation.number | 5 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | COVID-19 | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | SEVERITY | - |
dc.subject.keywordPlus | INJURY | - |
dc.subject.keywordAuthor | coronavirus disease 2019 | - |
dc.subject.keywordAuthor | unresectable hepatocellular carcinoma | - |
dc.subject.keywordAuthor | liver function | - |
dc.subject.keywordAuthor | atezolizumab | - |
dc.subject.keywordAuthor | bevacizumab | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.